CD8A and neoplasm: Previously, univariate and multivariate cox analysis of the ELARA study, employing tisagenleclucel (tisa-cel) in r/r FL patients showed that elevated tumor burden [TB; total metabolic tumor volume (TMTV) ≥ 240 cm3] at baseline (prelymphodepleting chemotherapy [pre-LD]), lower number of naive CD8+ T cells and more than 4 nodal areas at inclusion were clinical factors that correlated significantly with disease progression (5).